A new approach to target an 'undruggable' prostate cancer driver

New research suggests a novel strategy to target a genetic anomaly that occurs in half of all prostate cancers. When the genes TMPRSS2 and ERG relocate on a chromosome and fuse together, it's an on-switch for prostate cancer development. But ERG has...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mUSR3q
via IFTTT